Immunohistochemical Expression of Androgen Receptors (AR) in Various Breast Cancer Subtypes

Journal of Business & Economics Research (JBER)

View Publication Info
 
 
Field Value
 
Title Immunohistochemical Expression of Androgen Receptors (AR) in Various Breast Cancer Subtypes
 
Creator Ismael, Nour El Hoda S.
Khairy, Rasha A.
Talaat, Suzan M.
Abd El-Fattah, Fatima A.
 
Subject Androgen receptors
Breast cancer
Hormonal status
Immunohistochemistry
Luminal
Triple-negative
 
Description BACKGROUND: Breast carcinoma ranks the first among malignant tumours in females and is the chief cause of cancer-related mortality. Androgen in implicated in the induction of proliferation and growth of mammary cells through binding to their corresponding receptors. Androgens influence the risk of acquiring breast cancer through either direct binding to androgen receptors (AR) or indirectly through their transformation to estradiol or competing for steroid binding proteins.
AIM: To study the expression of AR in various breast cancer subtypes and to elucidate its clinical significance by correlating it with clinicopathological parameters.
METHODS: One hundred and fifty breast cancer cases were studied using AR immunohistochemistry, and its expression was correlated with different clinicopathologic parameters and with ER, PR, Her-2/neu and Ki 67 expression.
RESULTS: AR was expressed in 91 breast carcinoma cases out of 150 examined. There was a statistically significant correlation between AR expression and tumour size, mitotic count, tumour necrosis, infiltrative borders, the hormonal status of the tumour and subsequently luminal subtypes (p < 0.05). A subset of studied TNBC (34.6%) also expressed AR. On the other hand, there was no significant correlation between AR expression and other clinicopathological parameters.
CONCLUSION: Positive AR immunostaining was associated with favourable prognostic factors and luminal subtypes (A&B). Also, a subset of TNBC cases showed positive AR expression. These results introduce the current potent, next-generation AR- antagonist as possible target therapy in breast cancer. Further researches on AR expression in breast cancer are recommended on a larger scale with follow up and survival to validate the current results.
 
Publisher Scientific Foundation SPIROSKI, Skopje, Republic of Macedonia; ID Design 2012/DOOEL Skopje, Republic of Macedonia
 
Date 2019-04-29
 
Type info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
 
Format application/pdf
application/pdf
 
Identifier https://www.id-press.eu/mjms/article/view/oamjms.2019.311
10.3889/oamjms.2019.311
 
Source Open Access Macedonian Journal of Medical Sciences; Vol 7 No 8 (2019): Apr 30 (OAMJMS); 1259-1265
1857-9655
 
Language eng
 
Relation https://www.id-press.eu/mjms/article/view/oamjms.2019.311/3266
https://www.id-press.eu/mjms/article/view/oamjms.2019.311/3261
 
Rights Copyright (c) 2019 Nour El Hoda S. Ismael, Rasha A. Khairy, Suzan M. Talaat, Fatima A. Abd El-Fattah
https://creativecommons.org/licenses/by-nc/4.0
 

Contact Us

The PKP Index is an initiative of the Public Knowledge Project.

For PKP Publishing Services please use the PKP|PS contact form.

For support with PKP software we encourage users to consult our wiki for documentation and search our support forums.

For any other correspondence feel free to contact us using the PKP contact form.

Find Us

Twitter

Copyright © 2015-2018 Simon Fraser University Library